Gore Receives First FDA Approval for Endovascular Repair of Aortic Dissection

Conformable GORE® TAG® Thoracic Endoprosthesis First to Receive Indication for Aneurysm, Trauma and Dissection

Flagstaff, Ariz. (September 11, 2013) — W. L. Gore & Associates (Gore) today announced that the US Food and Drug Administration (FDA) has approved the Conformable GORE® TAG® Thoracic Endoprosthesis for endovascular repair of acute and chronic Type B dissections of the descending thoracic aorta. This durable endoprosthesis is the only device to receive FDA approval for this indication. The Conformable GORE TAG Thoracic Endoprosthesis is designed for multiple thoracic etiologies. Extensive clinical research has been conducted with the device and it is the one and only device to receive FDA indications for aneurysm, trauma and dissection.

An aortic dissection is the tearing of the innermost layer of the aortic wall, allowing blood to flow between the inner and outer layers of the vessel wall causing separation. If not stabilized, the dissection can increase the risk of rupture, cause complications with blood flow to the lower body and harm nearby organs. Until now, the only approved treatment options were medical management or open surgical repair.

"Vascular surgeons have for some time awaited an approved indication for treating certain Type B aortic dissection patients since the consensus has been that endovascular stent graft repair has emerged as the treatment of choice," said Richard Cambria, MD, Chief, Division of Vascular and Endovascular Surgery and Co-Director, Thoracic Aortic Center at the at the Massachusetts General Hospital Vascular Center in Boston. “Now, surgeons will be able to present patients with a minimally invasive treatment option and the exchange of information and experience among surgeons will be more acceptable now that the procedure is approved.”

“Having an FDA-approved Type B dissection indication is very important, as the impact this has on the endovascular community and the eligible patient population is huge,” said Joseph Bavaria, MD, Roberts / Measey Professor of Surgery, Vice Chair in the Division of Cardiovascular Surgery and Director of the Thoracic Aortic Surgery Program at the University of Pennsylvania. “I applaud Gore for recognizing the urgent need for an FDA-approved dissection indication and for being committed to conducting a thorough and expertly run clinical study.”

The Conformable GORE TAG Device offers conformability and ease of use, while accommodating tortuous and tapered anatomy. The device resists compression and has a broad oversizing window ranging from 6 to 33 percent. Physicians are able to choose the appropriate oversizing for the patient anatomy, which is particularly important in dissection patients due to the delicate nature of the disease.

The Conformable GORE TAG Thoracic Endoprosthesis is delivered via catheter and inserted into the femoral artery through a small incision in the groin and carefully guided up the leg artery through the abdomen into the chest and to the implantation site. The device is available in diameters of 21-45 mm, allowing for the treatment of patients with aortic diameters of 16-42 mm. Tapered device configurations are also available.

“Today’s approval further advances the use of endovascular devices as standard of care and allows more patients to benefit from this preferred treatment option,” said Ryan Takeuchi, Gore Aortic Business Leader. “Gore has always been on the cutting edge of endovascular treatment and was the first to gain approval for thoracic aortic aneurysm followed by aortic traumas using our Conformable GORE TAG Device. We are proud to offer surgeons another first with the only FDA-approved, minimally invasive treatment for Type B dissections.”

ABOUT W. L. GORE & ASSOCIATES

The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 35 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac, and general surgery. Gore is one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984. For more information, visit www.goremedical.com.

Products listed may not be available in all markets. GORE®, TAG®, and designs are trademarks of W. L. Gore & Associates. 
AS1193-EN1 SEPTEMBER 2013

 

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.